CDT Equity Inc. Net Assets
CDT Equity Inc. net assets. Based on the latest financial reports, CDT Equity Inc. (CDT) has net assets worth $1.38 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.50 Billion) and total liabilities ($2.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of CDT Equity Inc. to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.38 Billion |
| % of Total Assets | 39.51% |
| Annual Growth Rate | 1473.64% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of CDT Equity Inc. (2021–2025)
Net assets of CDT Equity Inc. from 2021 to 2025. This chart illustrates how CDT Equity Inc.'s net assets have evolved over time, based on quarterly financial data. See CDT Equity Inc. (CDT) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for CDT Equity Inc. (2021–2025)
The table below shows the annual net assets of CDT Equity Inc. from 2021 to 2025. For live market cap and overall valuation, see CDT Equity Inc. (CDT) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.26 Billion | +18713.63% |
| 2024-12-31 | $-6.79 Million | -1386.43% |
| 2023-12-31 | $-457.00K | +95.47% |
| 2022-12-31 | $-10.09 Million | -49030.60% |
| 2021-12-31 | $20.62K | -- |
Equity Component Analysis
This analysis shows how different components contribute to CDT Equity Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 140557638100.0% over the analyzed period, indicating profitable operations and earnings retention.
CDT Equity Inc. Net Assets Breakdown (December 2025)
CDT Equity Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.41 Billion | 111.16% |
| Common Stock | $503.00K | 0.04% |
| Other Comprehensive Income | $-97.20 Million | -7.69% |
| Total Equity | $1.26 Billion | 100.00% |
CDT Equity Inc. Competitors by Market Cap
The table below lists competitors of CDT Equity Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nvni Group Limited
NASDAQ:NVNIF
|
$409.39K |
|
Network Media Group Inc
V:NTE
|
$411.78K |
|
H&G High Conviction Ltd
AU:HCF
|
$411.94K |
|
LEGIBLE INC.
F:D0T
|
$412.41K |
|
in Style Group PLC
LSE:ITS
|
$406.88K |
|
Shoe Zone PLC
LSE:SHOE
|
$405.67K |
|
IMMOTION GRP LS-0004010
F:6XK
|
$405.65K |
|
Star Energy Group Plc
LSE:STAR
|
$405.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CDT Equity Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -6,793,000 to 1,264,424,000, a change of 1,271,217,000.
- Net loss of 39,224,000 reduced equity.
- Dividend payments of 7,966,000 reduced retained earnings.
- Share repurchases of 106,000 reduced equity.
- New share issuances of 19,699,000 increased equity.
- Other comprehensive income decreased equity by 97,618,000.
- Other factors increased equity by 1,396,432,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.22 Million | -3.1% |
| Dividends Paid | $7.97 Million | -0.63% |
| Share Repurchases | $106.00K | -0.01% |
| Share Issuances | $19.70 Million | +1.56% |
| Other Comprehensive Income | $-97.62 Million | -7.72% |
| Other Changes | $1.40 Billion | +110.44% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CDT Equity Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $86.06 | $0.40 | x |
| 2022-12-31 | $-7631.45 | $0.40 | x |
| 2023-12-31 | $-80.77 | $0.40 | x |
| 2024-12-31 | $-940.10 | $0.40 | x |
| 2025-12-31 | $379706.91 | $0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CDT Equity Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.44%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 2.80x
- Recent ROE (-3.10%) is above the historical average (-3547.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -17736.07% | 0.00% | 0.00x | 10.34x | $-3.66 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.88 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-489.30K |
| 2024 | 0.00% | -1.93% | 219.94x | 0.00x | $-17.12 Million |
| 2025 | -3.10% | -1.44% | 0.77x | 2.80x | $-165.67 Million |
Industry Comparison
This section compares CDT Equity Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $230,249,706
- Average return on equity (ROE) among peers: -88.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CDT Equity Inc. (CDT) | $1.38 Billion | -17736.07% | 1.53x | $407.55K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $28.96 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.75 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $138.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $15.46 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $45.35 Million | -59.09% | 0.17x | $810.25 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $24.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $18.59 Million | -164.77% | 1.78x | $7.50 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $627.01 Million | -44.91% | 0.25x | $3.23 Billion |
About CDT Equity Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more